Sub menu

 

 

TREMFYA (Janssen-Cilag Pty Ltd)

Product name
TREMFYA
Sponsor
Janssen-Cilag Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
210 (255 working days)
Active ingredients
guselkumab
Registration type
EOI
Indication
Plaque psoriasis

TREMFYA (tablet) is now also indicated for the treatment of adult patients with active psoriatic arthritis, who have had an inadequate response to, or are intolerant to prior DMARD therapy.

Help us improve this page